Gilead Sciences, Inc. [GILD] stock prices are down -0.56% to $66.93 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The GILD shares have lost -1.75% over the last week, with a monthly amount drifted -8.64%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Gilead Sciences, Inc. [NASDAQ: GILD] stock has seen the most recent analyst activity on February 22, 2024, when Truist downgraded its rating to a Hold and also revised its price target to $82 from $91. Previously, Deutsche Bank started tracking the stock with Hold rating on November 09, 2023, and set its price target to $75. On September 08, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $95 on the stock. HSBC Securities started tracking the stock assigning a Reduce rating and suggested a price target of $71 on September 06, 2023. Barclays reiterated its recommendation of a Equal Weight and reduced its price target to $80 on July 24, 2023. BMO Capital Markets upgraded its rating to Outperform for this stock on May 16, 2023, and upped its price target to $100.
The stock price of Gilead Sciences, Inc. [GILD] has been fluctuating between $67.18 and $87.86 over the past year. Currently, Wall Street analysts expect the stock to reach $79.25 within the next 12 months. Gilead Sciences, Inc. [NASDAQ: GILD] shares were valued at $66.93 at the most recent close of the market. An investor can expect a potential return of 18.41% based on the average GILD price forecast.
Analyzing the GILD fundamentals
The Gilead Sciences, Inc. [NASDAQ:GILD] reported sales of 27.06B for trailing twelve months, representing a drop of -2.75%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.25%, and Net Profit Margin reading is 0.21%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.26 and Total Capital is 0.17. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 66.70 points at the first support level, and at 66.46 for the second support level. However, for the 1st resistance point, the stock is sitting at 67.36, and for the 2nd resistance point, it is at 67.78.
Ratios To Look Out For
It’s worth pointing out that Gilead Sciences, Inc. [NASDAQ:GILD]’s Current Ratio is 1.43. On the other hand, the Quick Ratio is 1.27, and the Cash Ratio is 0.54. Considering the valuation of this stock, the price to sales ratio is 3.08, the price to book ratio is 3.65 and price to earnings (TTM) ratio is 14.86.
Transactions by insiders
Recent insider trading involved GILEAD SCIENCES, INC., 10% Owner, that happened on Apr 02 ’24 when 0.49 million shares were purchased. Chief Medical Officer, Parsey Merdad completed a deal on Apr 01 ’24 to sell 2000.0 shares. Meanwhile, Chief Medical Officer Parsey Merdad sold 8230.0 shares on Feb 29 ’24.
